Pembrolizumab (anti-PD-1)

目录号：A2005         批次号: A200509

打印

Pembrolizumab (anti-PD-1)是一种有效的、高选择性的、人源IgG4-kappa单克隆抗体，同时也是抑制剂，靶向PD-1，具有潜在的免疫检查点抑制活性和抗肿瘤活性；MW：146.286 KD。

抗体信息

CAS号 1374853-91-4
配制 PBS buffer, pH 7.2
推荐同型对照 Human IgG4
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 12.378mg/ml
内毒素 ＜1EU/mg

Pembrolizumab (anti-PD-1)在文献中得到引用

IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer [ Mol Cancer, 2025, 24(1):80] PubMed: 40091029
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer [ Nat Commun, 2025, 16(1):2374] PubMed: 40064880
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T-cells in uveal melanoma patients [ J Clin Invest, 2025, e181464] PubMed: 40311102
In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies [ J Nanobiotechnology, 2025, 23(1):411] PubMed: 40457452
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients [ Cell Death Dis, 2025, 16(1):286] PubMed: 40221409
Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma [ Br J Cancer, 2025, 10.1038/s41416-025-03185-0] PubMed: 41044172
Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication [ Cell Rep, 2025, 44(5):115584] PubMed: 40244846
Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma immunotherapy through STAT3-THBS1/CD47 pathway [ Front Immunol, 2025, 16:1612318] PubMed: 41019041
Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity [ Commun Biol, 2025, 8(1):621] PubMed: 40240529
Necroptosis-driven T cell activation promotes IL-6-mediated PD-L1 upregulation in cholangiocarcinoma cells: IL-6 gene signature as a biomarker for chemo-immunotherapy response [ Biol Direct, 2025, 20(1):98] PubMed: 40983928

禁止用于人体及治疗！